Macular Hole Surgery With Temporal Inverted Internal Limiting Membrane Flap (MARTIAL)

Sponsor
Central Hospital, Nancy, France (Other)
Overall Status
Unknown status
CT.gov ID
NCT03287102
Collaborator
(none)
130
1
2
24
5.4

Study Details

Study Description

Brief Summary

Since 1991, idiopathic macular holes (MH) can benefit from an effective treatment initially involving pars plana vitrectomy, stripping of epiretinal membranes and intraocular gas tamponade followed by facedown positioning. The initial 58% success rate has further increased to 85-100% with internal limiting membrane (ILM) peeling. However, complete ILM removal has been shown to lead to anatomic changes causing the retina to have the appearance of a dissociated optic nerve fiber layer (DONFL). Moreover, it has been associated with decreased retinal sensitivity that may cause visual discomfort despite good visual acuity. Nawrocki et al. recently suggested to reduce the area of peeled ILM (temporal inverted ILM flap technique) in order to minimize iatrogenic trauma while maintaining satisfactory surgical outcomes. The aim of this study is to compare the incidence of DONFL appearance and retinal sensitivity after macular hole surgery in eyes that underwent temporal inverted ILM flap technique and eyes that had complete ILM peeling

Condition or Disease Intervention/Treatment Phase
  • Procedure: Macular hole surgery
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
130 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Dissociated Optic Nerve Fiber Layer Appearance and Retinal Sensitivity After Macular Hole Surgery With Temporal Inverted Internal Limiting Membrane Flap Technique
Anticipated Study Start Date :
Feb 1, 2018
Anticipated Primary Completion Date :
Feb 1, 2020
Anticipated Study Completion Date :
Feb 1, 2020

Arms and Interventions

Arm Intervention/Treatment
Other: Temporal inverted ILM peeling group

The internal limiting membrane is peeled from the temporal side of the fovea only

Procedure: Macular hole surgery
Vitrectomy, temporal inverted or complete ILM peeling and gas tamponade

Other: Complete ILM peeling group

The internal limiting membrane is completely removed around the fovea

Procedure: Macular hole surgery
Vitrectomy, temporal inverted or complete ILM peeling and gas tamponade

Outcome Measures

Primary Outcome Measures

  1. Number of dimples on optical coherence tomography [3 months after surgery]

    Incidence of DONFL appearance

Secondary Outcome Measures

  1. Retinal sensitivity on microperimetry testing (decibel) [3 months after surgery]

  2. Macular hole closure rate on optical coherence tomography [3 months after surgery]

  3. Visual acuity (Logarithm of the Minimum Angle of Resolution) [3 months after surgery]

  4. Ellipsoide zone defect on optical coherence tomography [3 months after surgery]

  5. External limiting membrane defect on optical coherence tomography [3 months after surgery]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Patients older than 18 years old
Exclusion Criteria:
  • Underage patients

  • History of intraocular surgery (except for cataract surgery)

  • Macular hole secondary to trauma, diabetic retinopathy, uveitis or associated with retinal detachment

  • Concurrent macular disease (diabetic maculopathy, age-related macular degeneration)

Contacts and Locations

Locations

Site City State Country Postal Code
1 Brabois Hospital Vandœuvre-lès-Nancy France 54500

Sponsors and Collaborators

  • Central Hospital, Nancy, France

Investigators

  • Principal Investigator: Jean-Baptiste CONART, Brabois Hospital, Nancy, France

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Central Hospital, Nancy, France
ClinicalTrials.gov Identifier:
NCT03287102
Other Study ID Numbers:
  • 2017-A02061-52
First Posted:
Sep 19, 2017
Last Update Posted:
Jan 30, 2018
Last Verified:
Sep 1, 2017
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 30, 2018